Biological Therapy in Treating Patients With Advanced Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced malignancy that expresses HER2/neu
• * Stage IIA breast cancer with more than 6 positive lymph nodes
• * Stage IIB, IIIA, or IIIB breast cancer
• * Stage III ovarian cancer
• * Lymph node positive gastric cancer
• * Metastatic tumor
• No measurable or evaluable disease after standard treatment
• No previously irradiated or newly diagnosed CNS metastases
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Menopausal status:
• Not specified
• Performance status:
• Karnofsky 80-100%
• Life expectancy:
• Greater than 6 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Hemoglobin at least 9 mg/dL
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• No hepatic disease, including viral hepatitis
• Renal:
• Creatinine less than 2.5 mg/dL
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Pulmonary:
• No asthma or chronic obstructive pulmonary disease
• Immunologic:
• Must have positive intradermal delayed hypersensitivity test for at least 1 of the following:
• * Candida
• * Mumps
• * Tetanus
• * Trichophyton
• * Histoplasmin
• No prior autoimmune disease including, but not limited to, the following:
• * Inflammatory bowel disease
• * Systemic lupus erythematosus
• * Ankylosing spondylitis
• * Scleroderma
• * Multiple sclerosis
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• Hepatitis B surface antigen and hepatitis C antibody negative
• No other concurrent serious chronic or acute illness or infection (including urinary tract infection)
• No known shellfish or iodine allergy
• No other prior or concurrent malignancy except for nonmelanoma skin cancer, cervical cancer, or controlled superficial bladder cancer
• No medical or psychological condition that may preclude study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No other concurrent immunotherapy
• Chemotherapy:
• At least 4 weeks since prior chemotherapy and recovered
• No concurrent chemotherapy
• Endocrine therapy:
• Concurrent hormonal therapy allowed (tamoxifen, raloxifene, toremifene, and all aromatase inhibitors)
• At least 4 weeks since prior steroid or immunosuppressive therapy (e.g, azathioprine or cyclosporine)
• Radiotherapy:
• Prior radiotherapy allowed except to cranium
• At least 4 weeks since prior radiotherapy and recovered
• At least 12 weeks since prior strontium chloride Sr 89
• No concurrent radiotherapy
• Surgery:
• At least 4 weeks since prior surgery and recovered
• Other:
• Concurrent bisphosphonates allowed
• No prior hepatitis B immunization